We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » KING PHARMA TO RESTATE EARNINGS; MERGER WITH MYLAN IN DOUBT
KING PHARMA TO RESTATE EARNINGS; MERGER WITH MYLAN IN DOUBT
December 10, 2004
Brand firm King Pharmaceuticals has announced it will restate its earnings results for 2002, 2003 and the first six months of 2004 — a move that could allow generic firm, Mylan Laboratories to pull out of a deal to purchase King without having to pay an $85 million penalty fee.